- Joined
- Sep 28, 2017
- Messages
- 114
- Reaction score
- 48
I have seen pharmacogenomic reports showing methylphenidate listed with two separate results: ADRA2A and COMT. For instance, I'm looking at report right now which states the following details for methylphenidate:
Methylphenidate (ADRA2A): ADRA2A(C-1291G): C|C
Typical response is expected; no additional therapeutic recommendations.
and
Methylphenidate (COMT): COMT(Val158Met): Decreased function. Two alleles with decreased activity.
Individuals with the Met variant may be at an increased risk of therapeutic failure.
Anyone familiar with this? What am I to take away from it? I've tried reaching out to the company that runs this test, and they basically said that this medication is multigenetic and conclusive outcomes data for all combinations of both genes together does not yet exist, so the doctor will need to decide the best route of prescribing based on all of the data available.
Methylphenidate (ADRA2A): ADRA2A(C-1291G): C|C
Typical response is expected; no additional therapeutic recommendations.
and
Methylphenidate (COMT): COMT(Val158Met): Decreased function. Two alleles with decreased activity.
Individuals with the Met variant may be at an increased risk of therapeutic failure.
Anyone familiar with this? What am I to take away from it? I've tried reaching out to the company that runs this test, and they basically said that this medication is multigenetic and conclusive outcomes data for all combinations of both genes together does not yet exist, so the doctor will need to decide the best route of prescribing based on all of the data available.